Welcome, Guest. Please login or register.
May 26, 2019, 03:00:45 am

Login with username, password and session length


Members
  • Total Members: 6097
  • Latest: Sage
Stats
  • Total Posts: 54081
  • Total Topics: 4554
  • Online Today: 72
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 70
Total: 70

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Checkpoint Combination May Slow Liver and Biliary Tract Cancer  (Read 130 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 599
    • Hep Mag
A combination of two immune checkpoint inhibitors, Imfinzi (durvalumab) and tremelimumab, appeared to slow progression of advanced liver and biliary tract cancer in a small study, researchers reported at the 2019 Gastrointestinal Cancers Symposium this month in San Francisco. However—as seen in other studies of immunotherapy for these cancers—the overall response rates are low.

Over years or decades, chronic hepatitis B or C, heavy alcohol use, fatty liver disease and other causes of liver injury can lead to the development of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. HCC is often detected late and is hard to treat. Liver cancer does not respond well to traditional chemotherapy. Targeted therapy—including the standard first-line therapy, Nexavar (sorafenib)—and immunotherapy show some promise, but a majority of patients do not respond and mortality remains high. Biliary tract cancer, involving the gallbladder or bile ducts, is even more difficult to treat.

For more...
https://www.hepmag.com/article/checkpoint-combination-may-slow-liver-biliary-tract-cancer

 


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.